CMS has issued a March 12, 2026 correction to the CY 2026 Physician Fee Schedule (PFS), updating the CY 2026 PFS Final Rule Addendum B to address misclassified skin substitute HCPCS codes.
Starting January 1, 2026, CMS implemented several changes for Skin Substitutes in Medicare Part B. For details and background information, refer to blog posts "Skin Substitutes - What’s New in 2026? Navigating CMS Payment Changes" and "2026 CMS Rules for Skin Substitutes: Billing, Payment & Coverage FAQ".
Why are these updates relevant?
The PFS Addendum B lists whether CPT/HCPCS codes are payable, how they are reimbursed, and what RVUs and global periods apply. CMS identified that several skin substitute codes were misclassified or missing in Addendum B, which could have led to incorrect billing assumptions, underpayments or denials, and increased audit risk.
- Under CMS definitions (according to Addendum A):
- Status “A” = separately payable, with RVUs
- Status “C” = contractor-priced (no national RVUs)
- Status “E” = excluded (non-payable under PFS)
Which Skin Substitute HCPCS Codes Were Corrected in the March 12, 2026 CMS PFS Update?
1. Codes corrected to active, separately payable status (Status “A”)
Codes A2025, A2029, A2031, A2032, A2034, A2036, A2038, A2039, A4100 and Q4224 (Table 1) were previously listed with incorrect payment status and are now updated to:
- Procedure Status: A (Active)
- Non-Facility PE RVU: 3.81
- Total Non-Facility RVU: 3.81
Implication:
These codes are now recognized as separately payable under the PFS for both facility and non-facility care settings, and will be actively priced with an RVU for codes with this status (Procedure Status A)
Table 1. PFS Addendum B HCPCS codes corrected to active, separately payable status (Status “A”)
- A2025 Miro3d per cubic cm
- A2029 Mirotract matrix sheet
- A2031 Mirodry, per sq cm
- A2032 Myriad matrix, per sq cm
- A2034 Found drs solo, per sq cm
- A2036 Cohealyx col dml mx pr sq cm
- A2038 Marigen pacto, per sq cm
- A2039 Innovamatrix fd, per sq cm
- A4100 Skin sub fda clrd as dev nos
- Q4224 Hhf10-p per sq cm
|
2. Codes removed from Addendum B
Codes Q4106 and Q4226 were removed from Addendum B. Billing teams should verify their current reimbursement pathway before use.
- Q4106 Dermagraft
- Q4226 Myown harv prep proc sq cm
3. Codes corrected from non-payable to payable classification
Codes Q4398–Q4420 and Q4431, Q4432, Q4433 (Table 2) were previously assigned Status “E” (excluded/non-payable) in error and were previously omitted from Addendum B:
CMS has corrected these to be included under the PFS:
- Q4398–Q4420: active pricing (Procedure Status A)
- Q4431–Q4433: Status “C” (Procedure Status C: contractor-priced)
Implication:
Application of these products are no longer considered excluded from the PFS and may now be reimbursed:
- Either through national RVUs (if applicable)
- Or MAC-determined pricing (for contractor-priced codes)
Table 2. Addendum B HCPCS codes corrected from non-payable to payable classification
- Q4398 Summit ac per sq cm
- Q4399 Summit fx per sq cm
- Q4400 Polygon3 per sq cm
- Q4401 Absolv3 per sq cm
- Q4402 Xwrap 2.0 per sq cm
- Q4403 Xwrap dual plus per sq cm
- Q4404 Xwrap hydro plus per sq cm
- Q4405 Xwrap fenestra plus sq cm
- Q4406 Xwrap fenestra per sq cm
- Q4407 Xwrap tribus per sq cm
- Q4408 Xwrap hydro per sq cm
- Q4409 Amniomatrixf3x per sq cm
- Q4410 Amchomatrixdl per sq cm
- Q4411 Amniomatrixf4x per sq cm
- Q4412 Choriofix per sq cm
- Q4413 Cygnus solo per sq cm
- Q4414 Simplichor per sq cm
- Q4415 Alexiguard st-l per sq cm
- Q4416 Alexiguard tl-t per sq cm
- Q4417 Alexiguard dl-t per sq cm
- Q4418 Biolab wrap flow per sq cm
- Q4419 Biolab wrap flw lt per sq cm
- Q4420 Nuform per sq cm
- Q4431 Pma skin substitute, nos
- Q4432 510(k) skin subs, nos
- Q4433 361 hct/p skin subs, nos
|
4. Global period corrections
Codes Q4431, Q4432, Q4433 (see descriptions in Table 2) had their global period updated to ZZZ. This means that these codes are always included in the global period of a related service and are not separately paid when billed alone.
What does this update mean for wound care programs?
If programs generated claims involving the affected codes in 2026, these changes may have a direct impact on the revenue cycle.
- Claims involving the affected codes - particularly those submitted in early 2026 - should be reviewed for accuracy and may require correction or resubmission.
- Previously denied or underpaid claims related to the affected codes may now be eligible for appeal.
- In parallel, organizations should update their chargemaster and EHR systems to reflect the corrected coding, pricing, and status indicators. Ensure systems reflect:
- Correct Procedure Status (A vs C vs removed)
- Updated RVUs
- Correct global period indicators
Key takeaways
- Even after the PFS Final Rule is published, PFS data is not static.
- Small classification changes (particularly shifts between Status A, C, and E) can materially affect:
- Payment eligibility
- Billing workflows
- Audit exposure
- For skin substitutes, staying current with CMS corrections is essential to ensure accurate reimbursement and compliance.
What actions can wound care programs take after the CMS March 2026 PFS update?
- Review the updated PFS Addendum B (March 2026) once published. Of note, as of March 19, 2026, the file has not yet been updated on the CMS website despite the Federal Register correction notice.
- Audit claims involving affected codes
- Update internal coding and billing references
- Confirm MAC-specific pricing for contractor-priced codes
- If applicable, educate clinicians and billing teams on these changes
Resources
WoundReference
CMS
About the Authors
Elaine Horibe Song, MD, PhD, MBA
Dr. Song is a Co-Founder and Chief Executive Officer of WoundReference, Inc., a clinical and reimbursement decision support & telemedicine platform for wound care and hyperbaric clinicians. With a medical, science and business background, Dr. Song previously served as medical director for a regenerative medicine-focused biotech company in California, and for a Joint Commission International-accredited hospital network. Dr. Song also served as a management consultant for Kaiser Permanente, practiced as a plastic surgeon in private practice and academia, and conducted bench and clinical research in wound healing, microsurgery and transplant immunology. Dr. Song holds a position as Affiliate Professor, Division of Plastic Surgery, Federal University of Sao Paulo, and is a volunteer Communication/Website Committee, Association for the Advancement of Wound Care. She has authored more than 200 scientific publications, book chapters, software registrations and patents.
Tiffany Hamm, BSN, RN, CWS, ACHRN, UHMSADS
An Advanced Certified Hyperbaric Registered Nurse and Certified Wound Specialist with expertise in billing, coding and reimbursement specific to hyperbaric medicine and wound care services. UHMS Accreditation Surveyor and Safety Director. Principal partner of Midwest Hyperbaric LLC, a hyperbaric and wound consultative service. Tiffany received her primary and advanced hyperbaric training through National Baromedical Services in Columbia South Carolina. In 2021, Tiffany received the UHMS Associate Distinguished Service Award. "This award is presented to individual Associate member of the Society whose professional activities and standing are deemed to be exceptional and deserving of the highest recognition we can bestow upon them . . . who have demonstrated devotion and significant time and effort to the administrative, clinical, mechanical, physiological, safety, technical practice, and/or advancement of the hyperbaric community while achieving the highest level of expertise in their respective field. . . demonstrating the professionalism and ethical standards embodied in this recognition and in the UHMS mission.”